UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

An overlooked immune cell population may offer new direction for cell and gene therapy

Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.xxx:more

Arjan Gower receives NCCN grant to study a targeted therapy for early-stage NSCLC with rare EGFR mutations

Arjan Gower, a hematologist/oncologist at the UCLA Health Jonsson Comprehensive Cancer Center, received a $950,000 grant from the National Comprehensive Cancer Network and Taiho Oncology Inc. to help launch a multi-institutional clinical trial to test zipalertinib, an investigational drug that targets specific EGFR mutations, including Exon 20 insertions, which are known to drive cancer growth and resist standard treatments.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA preclinical study finds

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor-induced type 1 diabetes using an existing class of autoimmune drugs.

July 11, 2025

Vol.51 No.27

Clinical Roundup

UCLA study identifies key protein that helps liver cancer resist heat-based treatment

Galectin-1, a sugar-binding protein, plays a critical role in helping hepatocellular carcinoma resist thermal ablation and even thrive after being treated with high heat, according to a study from investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Cardiac biomarkers linked to future cancer risk, even without heart disease, says UCLA prospective cohort study

Certain cardiac blood markers can strongly predict future cancer risk—even in people with no history or symptoms of heart disease, according to a UCLA Health study.

July 11, 2025

Vol.51 No.27

In Brief

UCLA’s Roger Lo awarded $1 million to help prevent cancer relapse

Roger Lo, a professor of medicine, dermatology and molecular and medical pharmacology at the David Geffen School of Medicine at UCLA, has received a $1 million “All-Star” grant from the V Foundation to develop strategies to prevent relapse in patients with advanced melanoma by targeting drug resistance before it takes root.

July 03, 2025

Vol.51 No.26

UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

YOU MAY BE INTERESTED IN

An overlooked immune cell population may offer new direction for cell and gene therapy

Arjan Gower receives NCCN grant to study a targeted therapy for early-stage NSCLC with rare EGFR mutations

Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA preclinical study finds

UCLA study identifies key protein that helps liver cancer resist heat-based treatment

Cardiac biomarkers linked to future cancer risk, even without heart disease, says UCLA prospective cohort study

UCLA’s Roger Lo awarded $1 million to help prevent cancer relapse

Renew today!

Subscriber content

Never miss an issue!

Login